News and Trends 6 Dec 2022
Positive results from BioAge muscle atrophy trial
BioAge Labs, Inc. has announced positive phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. BGE-105 treatment resulted in statistically…